ABOUT VERISTAT, INC.
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique challenges associated with bringing cell and gene therapies to market. With experience in supporting over 100 cell and gene therapy trials, including the first gene therapy approved in Europe, Veristat is adept at strategy and execution across this complex clinical development pathway.
Veristat understands how high the stakes are with cell and gene therapy programs and that each therapy is unique, often coming with a complicated regulatory approval process and therapeutic challenges. We offer tailored solutions to combat these challenges, including:
- The ability to develop your therapeutic with accelerated approval pathways and/or special designations
- A review of operational aspects of the protocol and feedback on any potential obstacles that could impact the protocol execution at the clinical research sites
- Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
- Expertise in logistics and handling of live cellular material
- Long-term follow-up strategies to meet global regulatory requirements
The complexities of developing cell and gene therapies requires a committed and experienced partner. Veristat has assembled an extraordinary team of scientific experts worldwide who have mastered therapeutic development intricacies in this specialized area. Whatever the study’s unique considerations – patients, products, process, follow-up, regulatory – Veristat can successfully get you through it. For more information, visit www.veristat.com.
Groundbreaking Work Leads To First Gene Therapy Ever Approved In Europe
Veristat was brought in to create and manage a full development program for a gene therapy for a very rare inherited disorder. The work involved charting the course in completely uncharted waters – our team had to create industry best practices that didn’t exist before, anywhere. With no classic route to market, Veristat’s experts wrote the map on patient recruitment, regulatory and health agency engagement, natural history studies and the Central Site Model.
Supporting Multiple Global Gene Therapy Studies For Rare Diseases
A long-term client called upon the Veristat team for help conducting two investigational Phase I/II studies. These global studies focused on proving the safety and efficacy of gene therapy for two rare genetic disorders. Working side-by-side with the client, our cell and gene therapy experts addressed many complicated challenges – including site start-up issues, stringent regulatory requirements, and the logistics of handling highly sensitive genetic material.
Cell And Gene Therapy Team Guides Troubled Rare Disease Programs To Success
A clinical-stage biotechnology start-up asked Veristat to run a new European trial of their complex gene therapy. Veristat experts complimented the client’s team taking on their first clinical-stage program. Our global cell and gene therapy team brought knowledge in genetic material handling, relationships with key global regulatory agencies, and expertise in accelerated pathways to approval.
Stem Cell Therapy For Stroke Patients
A client engaged the Veristat team in a Phase II study of intracerebral stem cell injection in patients following an ischemic stroke. The goal was to look at limb recovery time and level in patients with stroke. The effort began with identifying the best time for a product to be delivered and then expanded into full-service involvement, including project management, clinical monitoring, medical writing, and regulatory affairs. Learn how we overcame unique challenges in this multi-center trial that led to the client publishing positive Phase IIa data.
Full Service Support For A Gene Therapy Trial
A clinical-stage biotechnology start-up asked Veristat to run complex US and EU trials of their unique gene therapy. Veristat brought invaluable global capabilities and expertise to a small client team tackling their first clinical-stage program without the large infrastructure or resources to conduct studies in this space themselves. Our end-to-end support started at Phase I and will continue into post-marketing and regulatory follow-up.